部分中文脑康平处方资料（仅供参考）

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（2009111223090126.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------

脑康平Aggrenox (aspirin 25mg + dipyridamole 200mg)--预防二度中风新药介绍

 Aggrenox (内含25mg aspirin及200mg dipyridamole)胶囊为最近在台湾上市用于预防二度暂时性脑血管缺血或缺血性脑中风药物。美国药物食品管理局于1999年11月22日核准Aggrenox胶囊在美国上市，核准剂量为每天两次，每次一颗胶囊。 Aggrenox内含两种不同机转的抗凝血药物;低剂量aspirin能选择性抑制cox脢在血小板的作用，增加PGI2浓度，提高抗凝血效果，而dipyridamole主要作用机转于细胞内,借抑制phosphodiesterase活性，增加cAMP细胞内的浓度，启动一连串抗凝血机转。两者相辅相乘，提高预防二度中风的效果。

根据大型ESPS-2(1)(2)针对预防二度中风的大型临床试验发现，6602位在试验前三个月内发生中风或TIA的受试者，在两年的follow-up期间发现，四组(1)aspirin 25mg bid: 1649 pts. (2)dipyridamole 200mg bid: 1654 pts.(3)aspirin 25mg+ dipyridamole 200mg bid: 1650 pts. (4)placebo bid: 1649 pts,每天两次服用指定药物的结果，Aspirin组及dipyridamole组达到降低二度中风统计上的意义，分别降低16%及18%机率，而aspirin + dipyridamole组和placebo相比，降低37%中风机率(p<0.001)。和aspirin组相比，降低23%机率(p=0.006)，其ARR(absolute risk reduction)两年为3%，也就是每年约1.5%。

一个分析所有aspirin+dipyridamole的meta-analysis(3) (包括ESPS-2)发现，aspirin+dipyridamole能降低约10%血管病变机率，而主要导因于降低非致命性中风发生的机率。

 Aggrenox是目前唯一合并aspirin及dipyridamole的药物，目前并无试验比较其与clopidogrel或ticlopidine预防二度中风的效果差异。但根据ESPS-2, TASS, CAPRIE三个分别针对Aggrenox, ticlopidine, clopidogrel的大型临床试验发现，Aggrenox似乎比另外两者在预防二度中风有较好的效果。

副作用方面,头痛(38%)是较常见的问题,而此问题可能导因于dipyridamole(原因不明)。在ESPS2试验中,有8%服用aspiring+dipyridamole的病人有头痛问题,而服用aspirin或placebo组约有2.1%机率。 (1)而另一个文献中发现(4),健康的人在服用Aggrenox每天两次,五天之后可以耐受这种短暂的头痛现象。其它副作用包括胃部不适(18%),恶心(16%),腹泻(13%)。

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（2009111223090126.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------

Aggrenox^® (aspirin/extended release dipyridamole) 25 mg/200 mg capsules, a prescription medication, is approved to reduce the risk of stroke in patients who have had a stroke or a TIA. AGGRENOX contains aspirin. Like aspirin, AGGRENOX should be avoided in the third trimester of pregnancy and should not be used in children or teenagers because of the risk of Reye's syndrome. Patients with a history of stomach ulcers should avoid using aspirin. Because AGGRENOX contains aspirin, the risk of bleeding is increased and it may take longer to stop bleeding. Patients who consume three or more alcoholic drinks every day should be aware of the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. Headache and stomach discomfort are common AGGRENOX side effects.

AGGRENOX is a prescription medication that is indicated to reduce the risk of a stroke recurrence after a TIA (transient ischemic attack) or stroke.

A stroke occurs when a blood clot blocks a blood vessel (known as an ischemic stroke) or when a blood vessel breaks (hemorrhagic stroke). When this happens, blood cannot get through to a section of the brain, so that part of the brain's oxygen supply is cut off. Within minutes, those brain cells die and abilities controlled by those cells are lost. A TIA is a brief episode of stroke-like symptoms with no lasting brain cell damage.

AGGRENOX makes platelets in the blood less sticky, so they don't clump together and form blood clots. AGGRENOX is the only prescription medication that is demonstrated to reduce the risk of stroke in patients who have had a TIA or an ischemic stroke.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（2009111223090126.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------

2009年11月12日更新